Healthtech startup Aiosyn, which is on a mission to leverage AI for improved clinical diagnostics, has just raised €2 million. The Dutch startup is now planning to accelerate its product launch.
Cancer is one of the most familiar illnesses there is. The sad reality is that the vast majority of us have been, or will be, personally affected by it and either diagnosed ourselves or have a close family member or friend that will fall ill. There have been some incredible breakthroughs in cancer treatment over the decades, however, there is still no cure. For most patients, the outcome of a cancer diagnosis really depends on the efficiency of being diagnosed in the first place.
Pathology is indispensable in the diagnosis process of many diseases, such as cancer. It generally involves the examination of tissue after a biopsy – and now, it’s entering a digital era.
Yvonne Sijm, investment manager at Health Innovations: “We believe that digital innovations enable the future of healthcare. Pathology plays an increasingly important role in many patient journeys. The solutions developed by Aiosyn support pathologists in providing high-quality decision-making. Aiosyn prepares the labour-intensive routine pathology tasks so that the pathologist can focus on the more interesting and complex tasks. This way, computational pathology not only makes life easier for pathologists, it also helps in addressing the scarcity challenges.”
Dutch startup Aiosyn has developed AI-based tech that will work in close synergy with pathologists to address the growing workload and the demand to further improve diagnostic precision – ultimately improving outcomes for patients. Now, the startup has secured new funding and is set to accelerate development.
- €2 million raised in a new investment
- The funding was led by Health Innovations together with Oost NL and LUMO Labs
Björn Schaap, investment manager Health at Oost NL: “Aiosyn’s pioneering platform technology has the potential to push the boundaries within pathology. Making the diagnosis of diseases more accurate, timely, and relevant, increases efficiency and gives the pathologist more time to focus on complex analyses. Therefore, it is my belief that the algorithms the Aiosyn team, a spin-out from Radboudumc, is developing will benefit patients. The tremendous development Aiosyn has made in the last year solidifies this belief, and for this reason, the company has the support of Oost NL.”
AI for Pathology
Founded in 2021 as a spin-off from the Computational Pathology Group of the Radboudumc in Nijmegen, the Netherlands, Aiosyn is taking an innovative new approach to pathology, using AI-based tech.
The startup has begun the development of two algorithms which can be used by pathologists to help them improve diagnostic precision, and make their work processes more efficient.
Patrick de Boer, CEO and co-founder of Aiosyn, explained: “The field of pathology is challenged by a growing workload and a shortage of pathologists. Aiosyn develops algorithms that work in close synergy with pathologists to improve the digital pathology workflow and clinical diagnostic tasks.”
The healthtech team has recently received ISO:13485 certification as a first step towards developing high-quality AI-based medical devices. Now, with this new funding, it will be able to accelerate product launch and prepare for the future product roadmap.
Sven Bakkes, partner at LUMO Labs: “We have noticed an uptake of AI in the healthcare industry in 2022. It is great to see the Aiosyn team making substantial progress and reaching this major milestone, securing this new round after our initial investment through the TTT.AI pre-seed fund. It will allow them to take the essential next steps on their way to make an impact on healthcare professionals and patients. We’ll be there to support them.”